WORCESTER, Mass.--(BUSINESS WIRE)--RXi Pharmaceuticals Corporation, a subsidiary of Cytrx Corporation (NASDAQ: CYTR), today announced that it has entered into an agreement with privately-held TriLink Biotechnologies, Inc. to exclusively license three RNA interference (RNAi) chemistry technologies for all therapeutic RNAi applications. The agreement includes rights to sublicense a patented RNA linker technology, a patent application on novel RNAi compositions and a novel, undisclosed chemistry approach that has potential to improve existing RNAi compounds.
